Trade representatives for Canada and Mexico met last week over the ratification and implementation of the United States–Mexico–Canada Agreement (USMCA), and press reports say that the Trump administration is considering acceding to Democrats’ demands to reduce patent protections for reference biologics in order to get the pact through Congress.
Trade representatives for Canada and Mexico met last week over the ratification and implementation of the United States—Mexico–Canada Agreement (USMCA), and press reports say that the Trump administration is considering acceding to Democrats’ demands to reduce patent protections for reference biologics in order to get the pact through Congress.
The USMCA was signed by the 3 countries on November 30, 2018, ostensibly as a replacement for the original North American Free Trade Agreement (NAFTA), just weeks after Democrats took control of the House of Representatives.
The biosimilars industry has been working since earlier this year to convince legislators to join them in opposing a pharmaceutical intellectual property provision in the USMCA. Currently, the provision would give 10 years of marketing exclusivity for biologic drugs.
Under US law, the period of exclusivity is 12 years; Democratic leaders in the House of Representatives want the time reduced to fewer than 10 years, possibly to 8 years.
Canada’s current exclusivity period for biologics is 8 and Mexico’s is 5, meaning that US biosimilar exports would have to wait longer if the additional timeframe in the USMCA passes.
The Association for Accessible Medicines has said that the USCMA will hinder generic and biosimilar competition, particularly as the manufacturing process for biosimilars becomes more efficient.
Mexico’s trade negotiator, Jesús Seade, spoke optimistically about the possibility of a deal on Twitter after the meeting with Canada, and was also said to have met with the US trade representative.
In the United States, the regulatory exclusivity provisions of the Biologics Price Competition and Innovation Act (BPCIA) already provide for a longer exclusivity period than required by the USMCA; the BPCIA provides 4 years of data exclusivity and 12 years of marketing exclusivity for reference biologic products
Representative Jim Himes, D-Connecticut, told The Wall Street Journal this week that a deal before Christmas is possible. But Senator Chuck Grassley, R-Iowa, chairman of the Senate Finance Committee, said that if a deal is not reached this week, he does not see how a 2019 ratification is possible.
Innovator biotechnology firms and pharmaceutical industry groups, such as the Biotechnology Innovation Organization, known as BIO, and the Pharmaceutical Research and Manufacturers of America, known as PhRMA, approve of the intellectual property language currently in the agreement.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.